We then analyzed the clinical REVEAL II cohort from Taiwan (23), which included 2,931 HCV-infected patients monitored for progression to HCC after treatment with peg-IFNα/RBV (Table 2). This evidence concerns the gene IFNA1 and hepatocellular carcinoma.